Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2005 2
2007 1
2009 1
2010 2
2011 5
2012 6
2013 3
2014 1
2015 5
2016 1
2017 1
2018 3
2019 3
2020 4
2021 2
2022 1
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean gwangpyo ko[Author] (134 results)?
Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study.
Kim KS, Han KA, Kim TN, Park CY, Park JH, Kim SY, Kim YH, Song KH, Kang ES, Kim CS, Koh G, Kang JG, Kim MK, Han JM, Kim NH, Mok JO, Lee JH, Lim S, Kim SS, Kim TH, Won KC, Lee KY, Cho JH, Han JY, Kim SH, Nah JJ, Song HR, Lee SE, Kim S; ENHANCE-D Investigators. Kim KS, et al. Among authors: koh g. Diabetes Metab. 2023 Jul;49(4):101440. doi: 10.1016/j.diabet.2023.101440. Epub 2023 Mar 9. Diabetes Metab. 2023. PMID: 36906135 Free article. Clinical Trial.
Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: Results of a 12-week, multicentre, randomized, double-blind, placebo-controlled, phase 2 trial.
Yang YS, Min KW, Park SO, Kim KS, Yu JM, Hong EG, Cho SR, Won KC, Kim YH, Oh S, Choi SH, Koh G, Huh W, Kim SY, Park KS. Yang YS, et al. Among authors: koh g. Diabetes Obes Metab. 2023 Aug;25(8):2096-2104. doi: 10.1111/dom.15080. Epub 2023 Apr 24. Diabetes Obes Metab. 2023. PMID: 37016484 Clinical Trial.
A double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study.
Ryang S, Kim SS, Bae JC, Han JM, Kwon SK, Kim YI, Nam-Goong IS, Kim ES, Kim MK, Lee CW, Yoo S, Koh G, Kwon MJ, Park JH, Kim IJ. Ryang S, et al. Among authors: koh g. Diabetes Obes Metab. 2022 Sep;24(9):1800-1809. doi: 10.1111/dom.14766. Epub 2022 Jun 9. Diabetes Obes Metab. 2022. PMID: 35581902 Free PMC article. Clinical Trial.
46 results